Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Chest

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/CHEST.123.1.28PMID 12527599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison

  2018cited by this paper
• Pulmonary disposition of tobramycin.

  2015cited by this paper
• Cystic Fibrosis

  2009cited by this paper
• Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

  2002cited by this paper
• Efficacy and safety of aerosolized tobramycin in cystic fibrosis

  2001cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.

  1999cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

  1999cited by this paper
• Improvement of nebulised antibiotic delivery in cystic fibrosis

  1999cited by this paper
• The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

  1998cited by this paper
• Aerosolized Antibiotics for Bacterial Lower Airway Infections: Principles, Efficacy, and Pitfalls

  1997cited by this paper
• Choosing a nebulizer for cystic fibrosis applications.

  1997cited by this paper
• The diagnosis of cystic fibrosis.

  1997cited by this paper
• A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

  1997cited by this paper
• RhDNase I aerosol deposition and related factors in cystic fibrosis.

  1997cited by this paper
• Drug Uptake in the Trachea

  1996cited by this paper
• TOBRAMYCIN SERUM CONCENTRATIONS AFTER AEROSOL AND ORAL ADMINISTRATION IN CYSTIC FIBROSIS

  1995cited by this paper
• Inhalation of antibiotics in cystic fibrosis.

  1995cited by this paper
• Diagnosis of cystic fibrosis.

  1995cited by this paper
• Nebulizer delivery of tobramycin to the lower respiratory tract

  1994cited by this paper
• The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis.

  1994cited by this paper
• Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

  1993cited by this paper
• Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage.

  1990cited by this paper
• Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

  1989cited by this paper
• Drug-induced ototoxicity.

  1988cited by this paper
• Standardization of spirometry--1987 update. Statement of the American Thoracic Society.

  1987cited by this paper
• Standardization of spirometry.

  1987cited by this paper
• Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

  1987cited by this paper
• Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

  1985cited by this paper
• Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum.

  1983cited by this paper
• Changes in the normal maximal expiratory flow-volume curve with growth and aging.

  1983cited by this paper
• Bronchial secretion concentrations of tobramycin.

  1982cited by this paper
• Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma.

  1981cited by this paper
• Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.

  1981cited by this paper
• Drug-induced Ototoxicity

  1980cited by this paper
• Guide for the Evaluation of Hearing Handicap

  1979cited by this paper
• Antibiotics in Cystic Fibrosis

  1964cited by this paper
• Serum and plasma.

  1947cited by this paper
• Serum and plasma.

  1947cited by this paper

• Development of a System to Deliver Inhalational Antibiotics to Marmosets

  2025cites this paper
• Inhaled combined antibacterials against biofilm-forming antibiotic-resistant bacteria for the management of pulmonary bacterial infections

  2024cites this paper
• Nebuliser systems for drug delivery in cystic fibrosis.

  2023cites this paper
• Scaling toward Diminutive MEMS: Dust‐Sized Spray Chips for Aerosolized Drug Delivery to the Lung

  2023cites this paper
• Understanding the suitability of established antibiotics for oral inhalation from a pharmacokinetic perspective: an integrated model-based investigation based on rifampicin, ciprofloxacin and tigecycline in vivo data.

  2022cites this paper
• Indian Guidelines on Nebulization Therapy.

  2022cites this paper
• The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in Pseudomonas aeruginosa Isolates in Cystic Fibrosis

  2021cites this paper
• Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment

  2021cites this paper
• Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions

  2021cites this paper
• The Impact of Pf Bacteriophages on the Fitness of Pseudomonas aeruginosa; A Mathematical Modeling Approach

  2020cites this paper
• University of Groningen Pharmacokinetics and safety of tobramycin nebulization with the I-neb® and PARI-LC Plus® in children with cystic fibrosis

  2019cites this paper
• Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: A randomized, crossover study

  2019cites this paper
• Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.

  2019cites this paper
• Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

  2019cites this paper
• Antimicrobial Activity of Ibuprofen Against 1 Cystic Fibrosis Associated Gram – Negative Pathogens 2 3

  2018cites this paper
• Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens

  2018cites this paper
• DEVELOPMENT AND VALIDATION OF A SEMI-PHYSIOLOGICAL PHARMACOKINETIC (PBPK) MODEL TO PREDICT SYSTEMIC AND PULMONARY EXPOSURES AFTER INTRAVENOUS, ORAL ADMINISTRATION AND PULMONARY INHALATION OF SELECTED DRUGS, BUDESONIDE, TOBRAMYCIN AND CIPROFLOXACIN, IN HUMANS

  2018cites this paper
• A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model

  2018cites this paper
• Assessment of recent nebulizer delivery systems using urinary pharmacokinetics method and aerodynamic characteristics of TOBI® nebulized dose following inhalation

  2017cites this paper
• Community Composition Determines Activity of Antibiotics against Multispecies Biofilms

  2017cites this paper
• In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.

  2016cites this paper
• Inhaled Antibiotics for Gram-Negative Respiratory Infections

  2016cites this paper
• The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.

  2015cites this paper
• Inhaled Formulation Design for the Treatment of Lung Infections.

  2015cites this paper
• Molecular mechanisms of persistence in Burkholderia cenocepacia biofilms

  2014cites this paper
• Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.

  2013cites this paper
• Nebuliser systems for drug delivery in cystic fibrosis.

  2013cites this paper
• Synthesis, Characterization, and In Vivo Efficacy of Shell Cross-Linked Nanoparticle Formulations Carrying Silver Antimicrobials as Aerosolized Therapeutics

  2013cites this paper
• Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid.

  2013cites this paper
• Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin

  2013cites this paper
• Tobramycin Disposition in the Rat Lung Following Airway Administration

  2013cites this paper
• 18 – Drug Administration by Inhalation in Children

  2012cites this paper
• Optimisation of inhaled corticosteroid delivery to asthmatic children: integration of in vitro and in vivo methods

  2012cites this paper
• AMINOGLYCOSIDE SUSCEPTIBILITY AND ACQUIRED RESISTANCE IN

  2012cites this paper
• Aerosolized antimicrobial agents based on degradable dextran nanoparticles loaded with silver carbene complexes.

  2012cites this paper
• Fitness Landscape of Antibiotic Tolerance in Pseudomonas aeruginosa Biofilms

  2011cites this paper
• Treatment options for cystic fibrosis: state of the art and future perspectives.

  2011cites this paper
• Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.

  2011cites this paper
• Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation

  2011cites this paper
• Microbiological insights into respiratory infections and the opportunities for inhaled therapy

  2011cites this paper
• Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections

  2011cites this paper
• Higher Tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis

  2011cites this paper
• Aerosol drug delivery: developments in device design and clinical use.

  2011cites this paper
• Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review

  2011cites this paper
• Performance of PARI eFlow®To the Editor

  2010cites this paper
• Short Communication Serum tobramycin levels following delivery of tobramycin (Tobi®) via eFlow® advanced nebuliser in children with cystic fibrosis ☆

  2010cites this paper
• Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery

  2010cites this paper
• Pulmonary drug delivery systems for antimicrobial agents: facts and myths.

  2010cites this paper
• Deliveryofantibioticstothe respiratorytract:anupdate

  2009cites this paper
• Aerosol Antibiotics in Cystic Fibrosis

  2009cites this paper
• In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.

  2009cites this paper
• New Aerosol Delivery Devices for Cystic Fibrosis

  2009cites this paper
• Delivery of antibiotics to the respiratory tract: an update

  2009cites this paper
• Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis.

  2009cites this paper
• Studies on antibiotic aerosols for inhalation in cystic fibrosis

  2009cites this paper
• Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.

  2009cites this paper
• Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

  2009cites this paper
• The clinical efficacy of inhalation therapy for respiratory infection

  2009cites this paper
• Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.

  2009cites this paper
• The antimicrobial efficacy of sustained release silver-carbene complex-loaded L-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies.

  2009cites this paper
• Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: A pilot project

  2008cites this paper
• Aerosolization of Tobramycin (TOBI®) with the PARI LC PLUS® Reusable Nebulizer: Which Compressor to Use? Comparison of the CR60® to the PortaNeb® Compressor

  2008influential citation
• The Role of Aerosolized Antimicrobials in the Treatment of Ventilator-Associated Pneumonia

  2007cites this paper
• [Aerosol: present and future].

  2007cites this paper
• Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa

  2007cites this paper
• Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection

  2007cites this paper
• Biodegradable nanoparticle flocculates for dry powder aerosol formulation.

  2007cites this paper
• Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature

  2007cites this paper
• Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety

  2007cites this paper
• Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.

  2007cites this paper
• Aérosols : présent et futur

  2007cites this paper
• Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa.

  2006cites this paper
• Aerosolised antibiotics: a critical appraisal of their use

  2006cites this paper
• Mechanism of Enhanced Activity of Liposome-Entrapped Aminoglycosides against Resistant Strains of Pseudomonas aeruginosa

  2006cites this paper
• Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.

  2006cites this paper
• Chapter 16 – Drug Administration by Aerosol in Children

  2006cites this paper
• Advanced techniques in the diagnosis and management of infectious pulmonary diseases in horses.

  2006cites this paper
• UCSF TREATMENT GUIDELINES FOR HOSPITAL MANAGEMENT OF ADULTS WITH CYSTIC FIBROSIS

  2005cites this paper
• Liquid-spray or dry-powder systems for inhaled delivery of peptide and proteins?

  2005cites this paper
• Nebulized antibiotic therapy: the evidence

  2005cites this paper
• Trends in the technology-driven development of new inhalation devices.

  2005cites this paper
• Controlled inhalation of aerosolised therapeutics

  2005cites this paper
• Antimikrobielle Aerosoltherapie bei Bronchiektasen?

  2004cites this paper
• Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency.

  2004cites this paper
• Inhalation of tobramycin in a patient with aspiration pneumonia as a result of medullary stroke

  2004cites this paper
• Aerosolized Antibiotics in Cystic Fibrosis

  2003cites this paper
• Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

  2003cites this paper
• Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis.

  2003cites this paper
• Status of combination therapy for refractorymycoses Related review : Status of combination therapy for refractory mycoses

  2003cites this paper